Sutimlimab's own cost-effectiveness evidence, not a rival drug, sets the pricing discipline a second CAD entrant will face.
Sutimlimab (Enjaymo) is dispensed as a weight-based intravenous infusion every two weeks and is billed through the Medicare Part B medical benefit as a physician-administered biologic under buy-and-bill, rather than through the Part D pharmacy benefit. At a reported wholesale acquisition cost of roughly $1,800 per 1,100-mg vial, annual therapy runs $259,000 to $302,000 per patient depending on body weight, placing cold agglutinin disease among the highest per-patient-cost rare-disease indications in US medicine despite a prevalent population of only a few thousand patients.
A peer-reviewed US cost-effectiveness analysis found sutimlimab's incremental cost-effectiveness ratio at $2.34 million per QALY against a standard $150,000 willingness-to-pay threshold, with standard of care favored over sutimlimab in all 10,000 iterations of a probabilistic sensitivity analysis. The same analysis concluded that sutimlimab would need roughly an 80% price reduction, or a treatment duration capped near 1.5 years, to meet standard cost-effectiveness benchmarks. Cold agglutinin disease has not been the subject of a formal ICER institute review, so this academic analysis stands as the primary published value reference any pricing strategy for this indication must clear.
US CAD pricing — sutimlimab's cost, routing, and published value verdict
| Dimension | Sutimlimab (Enjaymo) |
|---|---|
| WAC | ~$1,800 per 1,100-mg vial |
| Annual cost of therapy | $259,000-$302,000 per patient (weight-dependent) |
| Benefit routing | Medicare Part B — physician-administered biologic (buy-and-bill) |
| Cost-effectiveness (ICER) | $2.34M/QALY vs $150,000 WTP threshold; SOC favored in 100% of 10,000 PSA iterations |
| Path to value | ~80% price reduction, or treatment duration capped near 1.5 years |
Sources: FDA Drugs@FDA (sutimlimab/Enjaymo, BLA761164, Recordati Rare Diseases); WAC and annual cost per Berentsen, Immunotherapy 2022; cost-effectiveness analysis per American Journal of Hematology 2024 (PMID 38733355); Medicare Part B benefit classification for physician-administered biologics.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The WAC-to-annual-cost calculation across the weight-dependent dosing range
- Part B physician-administered buy-and-bill mechanics
- site-of-care and reimbursement implications
Delivers
- The ICER methodology behind the $2.34M/QALY figure
- the 100% probabilistic-sensitivity-analysis finding
- context against the standard $150,000 willingness-to-pay threshold
Delivers
- The ~80% price-reduction finding
- the capped-treatment-duration alternative
- outcomes-based contracting design implications for a new entrant
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why the $2.34M/QALY cost-effectiveness finding, not a rival drug, is the constraint a new entrant must clear
- Pressure-tested against sutimlimab's own published value evidence before the rest of the model is built out
- Reported WAC of roughly $1,800 per 1,100-mg vial translated into a $259,000-$302,000 weight-dependent annual cost
- Where cold agglutinin disease ranks among high-cost rare-disease indications
- Physician-administered IV infusion routing through the Part B medical benefit rather than Part D
- Site-of-care economics and reimbursement mechanics for an indefinite biweekly infusion
- ICER methodology and the $150,000 willingness-to-pay threshold comparison
- Standard of care favored in all 10,000 probabilistic-sensitivity iterations
- The ~80% price-reduction finding needed to meet standard cost-effectiveness benchmarks
- The alternative: a treatment duration capped near 1.5 years
- Net-price scenarios built against the 80% reduction finding
- Outcomes-based and duration-capped contracting structures payers could require
- Conservative, base, and aggressive revenue scenarios tied to the small prevalent population
- Budget-impact framing for a payer negotiating against the published ICER
- The open pricing questions your team must close before a launch price is locked
- Structured for an internal pricing committee session
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx pricing model is built from primary sources, FDA regulatory documentation, peer-reviewed cost-effectiveness literature, and Medicare benefit-classification rules, not secondary summaries. Findings are independently verified before inclusion.
Cold agglutinin disease US pricing sources: FDA Drugs@FDA and the sutimlimab label, published WAC and annual-cost data (Immunotherapy 2022), the peer-reviewed US cost-effectiveness analysis (Am J Hematol 2024, PMID 38733355), and CMS Part B benefit-routing rules for physician-administered biologics.
- Sutimlimab WAC and weight-dependent annual cost verified against published pricing data (Immunotherapy 2022, Berentsen review)
- Medicare Part B buy-and-bill routing verified against CMS benefit-classification rules for physician-administered IV biologics
- $2.34M/QALY ICER and the 100% probabilistic-sensitivity finding verified against Am J Hematol 2024 (PMID 38733355)
- The ~80% price-reduction and 1.5-year duration-cap conclusions verified against the same peer-reviewed cost-effectiveness analysis
Frequently asked questions
Commission this model
AXLRx delivers cold agglutinin disease pricing strategy models built for market access and pricing teams navigating Part B routing and cost-effectiveness scrutiny. Custom model in 72 hours.
Specify your indication, market basket, and comparator scope.
AXLRx analyst confirms pricing mechanism assumptions and WTP threshold before building.
Research-verified pricing model in 72 hours with optional analyst readout.